Cargando…

Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue

OBJECTIVE: To date, no safe and effective pharmacological treatment has been clinically validated for improving post-stroke neurogenesis. Growth factors are good candidates but low safety has limited their application in the clinic. An additional restraint is the delivery route. Intranasal delivery...

Descripción completa

Detalles Bibliográficos
Autores principales: Colitti, Nina, Desmoulin, Franck, Le Friec, Alice, Labriji, Wafae, Robert, Lorenne, Michaux, Amandine, Conchou, Fabrice, Cirillo, Carla, Loubinoux, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345199/
https://www.ncbi.nlm.nih.gov/pubmed/35928573
http://dx.doi.org/10.3389/fncel.2022.871532
_version_ 1784761376362725376
author Colitti, Nina
Desmoulin, Franck
Le Friec, Alice
Labriji, Wafae
Robert, Lorenne
Michaux, Amandine
Conchou, Fabrice
Cirillo, Carla
Loubinoux, Isabelle
author_facet Colitti, Nina
Desmoulin, Franck
Le Friec, Alice
Labriji, Wafae
Robert, Lorenne
Michaux, Amandine
Conchou, Fabrice
Cirillo, Carla
Loubinoux, Isabelle
author_sort Colitti, Nina
collection PubMed
description OBJECTIVE: To date, no safe and effective pharmacological treatment has been clinically validated for improving post-stroke neurogenesis. Growth factors are good candidates but low safety has limited their application in the clinic. An additional restraint is the delivery route. Intranasal delivery presents many advantages. MATERIALS AND METHODS: A brain lesion was induced in twenty-four rats. Nerve growth factor (NGF) 5 μg/kg/day or vehicle was given intranasally from day 10 post-lesion for two periods of five weeks, separated by a two-week wash out period with no treatment. Lesion volume and atrophy were identified by magnetic resonance imaging (MRI). Anxiety and sensorimotor recovery were measured by behavior tests. Neurogenesis, angiogenesis and inflammation were evaluated by histology at 12 weeks. RESULTS: Remarkable neurogenesis occurred and was visible at the second and third months after the insult. Tissue reconstruction was clearly detected by T2 weighted MRI at 8 and 12 weeks post-lesion and confirmed by histology. In the new tissue (8.1% of the lesion in the NGF group vs. 2.4%, in the control group at 12 weeks), NGF significantly increased the percentage of mature neurons (19% vs. 7%). Angiogenesis and inflammation were not different in the two groups. Sensorimotor recovery was neither improved nor hampered by NGF during the first period of treatment, but NGF treatment limited motor recovery in the second period. INTERPRETATION: The first five-week period of treatment was very well tolerated. This study is the first presenting the effects of a long treatment with NGF and has shown an important tissue regeneration rate at 8 and 12 weeks post-injury. NGF may have increased neuronal differentiation and survival and favored neurogenesis and neuron survival through subventricular zone (SVZ) neurogenesis or reprogramming of reactive astrocytes. For the first time, we evidenced a MRI biomarker of neurogenesis and tissue reconstruction with T2 and diffusion weighted imaging.
format Online
Article
Text
id pubmed-9345199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93451992022-08-03 Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue Colitti, Nina Desmoulin, Franck Le Friec, Alice Labriji, Wafae Robert, Lorenne Michaux, Amandine Conchou, Fabrice Cirillo, Carla Loubinoux, Isabelle Front Cell Neurosci Neuroscience OBJECTIVE: To date, no safe and effective pharmacological treatment has been clinically validated for improving post-stroke neurogenesis. Growth factors are good candidates but low safety has limited their application in the clinic. An additional restraint is the delivery route. Intranasal delivery presents many advantages. MATERIALS AND METHODS: A brain lesion was induced in twenty-four rats. Nerve growth factor (NGF) 5 μg/kg/day or vehicle was given intranasally from day 10 post-lesion for two periods of five weeks, separated by a two-week wash out period with no treatment. Lesion volume and atrophy were identified by magnetic resonance imaging (MRI). Anxiety and sensorimotor recovery were measured by behavior tests. Neurogenesis, angiogenesis and inflammation were evaluated by histology at 12 weeks. RESULTS: Remarkable neurogenesis occurred and was visible at the second and third months after the insult. Tissue reconstruction was clearly detected by T2 weighted MRI at 8 and 12 weeks post-lesion and confirmed by histology. In the new tissue (8.1% of the lesion in the NGF group vs. 2.4%, in the control group at 12 weeks), NGF significantly increased the percentage of mature neurons (19% vs. 7%). Angiogenesis and inflammation were not different in the two groups. Sensorimotor recovery was neither improved nor hampered by NGF during the first period of treatment, but NGF treatment limited motor recovery in the second period. INTERPRETATION: The first five-week period of treatment was very well tolerated. This study is the first presenting the effects of a long treatment with NGF and has shown an important tissue regeneration rate at 8 and 12 weeks post-injury. NGF may have increased neuronal differentiation and survival and favored neurogenesis and neuron survival through subventricular zone (SVZ) neurogenesis or reprogramming of reactive astrocytes. For the first time, we evidenced a MRI biomarker of neurogenesis and tissue reconstruction with T2 and diffusion weighted imaging. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9345199/ /pubmed/35928573 http://dx.doi.org/10.3389/fncel.2022.871532 Text en Copyright © 2022 Colitti, Desmoulin, Le Friec, Labriji, Robert, Michaux, Conchou, Cirillo and Loubinoux. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Colitti, Nina
Desmoulin, Franck
Le Friec, Alice
Labriji, Wafae
Robert, Lorenne
Michaux, Amandine
Conchou, Fabrice
Cirillo, Carla
Loubinoux, Isabelle
Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title_full Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title_fullStr Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title_full_unstemmed Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title_short Long-Term Intranasal Nerve Growth Factor Treatment Favors Neuron Formation in de novo Brain Tissue
title_sort long-term intranasal nerve growth factor treatment favors neuron formation in de novo brain tissue
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345199/
https://www.ncbi.nlm.nih.gov/pubmed/35928573
http://dx.doi.org/10.3389/fncel.2022.871532
work_keys_str_mv AT colittinina longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT desmoulinfranck longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT lefriecalice longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT labrijiwafae longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT robertlorenne longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT michauxamandine longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT conchoufabrice longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT cirillocarla longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue
AT loubinouxisabelle longtermintranasalnervegrowthfactortreatmentfavorsneuronformationindenovobraintissue